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Par-1 is an evolutionarily conserved protein kinase required for polarity in worms, flies, frogs, and mam-
mals. The mammalian Par-1 family consists of four members. Knockout studies of mice implicate Par-1b/
MARK2/EMK in regulating fertility, immune homeostasis, learning, and memory as well as adiposity, insulin
hypersensitivity, and glucose metabolism. Here, we report phenotypes of mice null for a second family member
(Par-1a/MARK3/C-TAK1) that exhibit increased energy expenditure, reduced adiposity with unaltered glucose
handling, and normal insulin sensitivity. Knockout mice were protected against high-fat diet-induced obesity
and displayed attenuated weight gain, complete resistance to hepatic steatosis, and improved glucose handling
with decreased insulin secretion. Overnight starvation led to complete hepatic glycogen depletion, associated
hypoketotic hypoglycemia, increased hepatocellular autophagy, and increased glycogen synthase levels in
Par-1a/ but not in control or Par-1b/ mice. The intercrossing of Par-1a/ with Par-1b/ mice revealed
that at least one of the four alleles is necessary for embryonic survival. The severity of phenotypes followed a
rank order, whereby the loss of one Par-1b allele in Par-1a/ mice conveyed milder phenotypes than the loss
of one Par-1a allele in Par-1b/ mice. Thus, although Par-1a and Par-1b can compensate for one another
during embryogenesis, their individual disruption gives rise to distinct metabolic phenotypes in adult mice.
Cellular polarity is a fundamental principle in biology (6, 36,
62). The prototypical protein kinase originally identified as a
regulator of polarity was termed partitioning defective (Par-1)
due to early embryonic defects in Caenorhabditis elegans (52).
Subsequent studies revealed that Par-1 is required for cellular
polarity in worms, flies, frogs, and mammals (4, 17, 58, 63, 65,
71, 89). An integral role for Par-1 kinases in multiple signaling
pathways has also been established, and although not formally
addressed, multifunctionality for individual Par-1 family mem-
bers is implied in reviews of the list of recognized upstream
regulators and downstream substrates (Table 1). Interestingly,
for many Par-1 substrates the phosphorylated residues gener-
ate 14-3-3 binding sites (25, 28, 37, 50, 59, 61, 68, 69, 78, 95,
101, 103). 14-3-3 binding in turn modulates both nuclear/cyto-
plasmic as well as cytoplasmic/membrane shuttling of target
proteins, thus allowing Par-1 activity to establish intracellular
spatial organization (15, 101). The phosphorylation of Par-1
itself promotes 14-3-3 binding, thereby regulating its subcellu-
lar localization (37, 59, 101).
The mammalian Par-1 family contains four members (Table
2). Physiological functions of the Par-1b kinase have been
studied using targeted gene knockout approaches in mice (9,
44). Two independently derived mouse lines null for Par-1b
have implicated this protein kinase in diverse physiological
processes, including fertility (9), immune system homeostasis
(44), learning and memory (86), the positioning of nuclei in
pancreatic beta cells (35, 38), and growth and metabolism (43).
Beyond Par-1b, most information regarding the cell biolog-
ical functions of the Par-1 kinases comes from studies of Par-
1a. Specifically, Par-1a has been implicated in pancreatic (76)
and hepatocarcinogenesis (51), as well as colorectal tumors
(77), hippocampal function (100), CagA (Helicobacter pylori)-
associated epithelial cell polarity disruption (82), and Peutz-
Jeghers syndrome (48), although the latter association has
been excluded recently (27). As a first step toward determining
unique and redundant functions of Par-1 family members,
mice disrupted for a second member of the family (Par-1a/
MARK3/C-TAK1) were generated. We report that Par-1a/
mice are viable and develop normally, and adult mice are
hypermetabolic, have decreased white and brown adipose tis-
sue mass, and unaltered glucose/insulin handling. However,
when challenged by a high-fat diet (HFD), Par-1a/ mice
* Corresponding author. Mailing address: Department of Cell Biol-
ogy and Physiology, Washington University School of Medicine, Box
8228, 660 South Euclid Ave., St. Louis, MO 63110. Phone: (314)
362-6812. Fax: (314) 362-3709. E-mail: hpiwnica@wustl.edu.
† These authors contributed equally to this study.
‡ Present address: Department of Pathology, Massachusetts Gen-
eral Hospital/Harvard Medical School, Boston, MA 02114-2621.
§ Present address: Agios Pharmaceuticals, Cambridge, MA 02139-
4169.
 Published ahead of print on 23 August 2010.
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exhibit resistance to hepatic steatosis, resistance to glucose
intolerance, and the delayed onset of obesity relative to that of
control littermates. Strikingly, overnight starvation results in a
complete depletion of glycogen and lipid stores along with an
increase in autophagic vacuoles in the liver of Par-1a/ but
not Par-1b/ mice. Correspondingly, Par-1a/ mice develop
hypoketotic hypoglycemia. These findings reveal unique met-
abolic functions of two Par-1 family members.
MATERIALS AND METHODS
Animal procedures. The Washington University School of Medicine Animal
Studies Committee approved all animal procedures. Unless stated otherwise,
animals were fed a standard chow diet (Lab Diet 5063 containing 4.5% fat, 55%
carbohydrate, 20% protein, and 4.7% fiber; Purina Mills, St. Louis, MO) and
were housed with free access to food and water under a 12-h light/dark cycle.
Unless indicated, only male mice were analyzed throughout this study.
Construction of the Par-1a targeting construct. A Par-1a genomic clone was
isolated from a 129X1/SvJ mouse embryonic stem (ES) cell genomic library by
hybridization with an isogenic 0.9-kb Par-1a-specific cDNA probe. The genomic
organization of the mouse Par-1a gene was disrupted by replacing a 1.9-kb
SacI/HpaI fragment with a 1.2-kb neomycin phosphotransferase cassette (Fig.
1A). The replacement disrupts exon 2 encoding the ATP binding domain of
Par-1a and also destroys the 5 splice site between introns 2 and 3. The insertion
of the neomycin selection cassette alters the PstI fragment from a single 13.8-kb
fragment to two fragments of 7.5 and 5.9 kb, and this change was used to identify
targeted ES cell clones and knockout (KO) animals by Southern blotting (Fig.
1B) using the 5 and 3 probes indicated in Fig. 1A. Using mouse genomic DNA
as the template, the 425-bp 5 probe was amplified by PCR with primers of
5-TGGTGGTACACGCCTGTATTC and 5-CTGATCTACACAATTCCAG
GAC. The 204 bp of 3 probe was amplified by PCR with primers of 5-GCAT
CTTGGGCTGTAAGTGATG and 5-GGCTTACAACCATCTGTACAG.
PCR analysis. PCR of tail DNA/tissues was achieved using a three-primer
PCR with one 5 primer from exon 2 (5-GGAGACGGGAGGCAAGAAGT
CA), a 3 primer from the intronic sequence between exons 2 and 3 (5-GGCT
CATTCCCTTGGTGTACTT), and a 3 primer from the neomycin cassette
(5GAGCAGCCGATTGTCTGTTGT), resulting in 400-bp (KO) or 300-bp
(wild-type [WT]) bands, respectively (Fig. 1C).
Generation of mice harboring the Par-1a mutation. RW4 ES cells were elec-
troporated with linearized targeting vector and selected with Geneticin (G418;
Invitrogen) using established protocols developed in the Murine Embryonic
Stem Cell Core of the Alvin J. Siteman Cancer Center at Washington University
School of Medicine and Barnes-Jewish Hospital (details are available at http:
TABLE 1. Multifunctionality of Par-1 polarity kinase pathwaysa
Regulator or substrate Function Reference(s)
Regulators (upstream function)
LKB1 Wnt signaling, Peutz-Jeghers syndrome, insulin signal transduction, pattern
formation
2, 63, 93
TAO1 MEK3/p38 stress-responsive mitogen-activated protein kinase (MAPK)
pathway
46
MARKK Nerve growth factor signaling in neurite development and differentiation 98
aPKC Ca2/DAG-independent signal transduction, cell polarity, glucose
metabolism
14, 37, 40, 45, 59, 75, 95
nPKC/PKD DAG-dependent, Ca2-independent signal transduction (GPCR) 101
PAR-3/PAR-6/aPKC (); regulates Par-1, assembly of microtubules, axon-dendrite specification 19
GSK3 (); tau phosphorylation, Alzheimer’s dementia, energy metabolism, body
patterning
54, 97
Pim-1 oncogene (); G2/M checkpoint, effector of cytokine signaling and Jak/STAT(3/5) 5
CaMKI (); Ca2-dependent signal transduction, neuronal differentiation 99
Substrates (downstream function)
Cdc25C Regulation of mitotic entry by activation of the cdc2-cyclin B complex 25, 72, 78, 103
Class II HDAC Control of gene expression and master regulator of subcellular trafficking 28, 50
CRTC2/TORC2 Gluconeogenesis regulator via LKB1/AMPK/TORC2 signaling, PPAR1a
coactivator
49
Dlg/PSD-95 Synaptogenesis and neuromuscular junction, tumor suppressor (102) 104
Disheveled Wnt signaling, translocation of Dsh from cytoplasmic vesicles to cortex 73, 94
KSR1 Regulation of the Ras-MAPK pathway 68, 69
MAP2/4/TAU Dynamic instability (67, 83) of microtubules, Alzheimer’s dementia (30) 11, 31–33, 47, 70, 96
Mib/Notch Mind bomb (Mib degradation and repression of Notch signaling results in
neurogenesis)
57, 74, 81
Par3/OSKAR/Lgl Cytoplasmic protein segregation, cell polarity, and asymmetric cell division 7, 10
Pkp2 Desmosome assembly and organization; nuclear shuttling 68, 69
PTPH1 Linkage between Ser/Thr and Tyr phosphorylation-dependent signaling 103
Rab11-FIP Regulation of endocytosis (23), trafficking of E-cadherin (64) 34
a LKB1 also is known as Par-4; MARKK also is known as Ste20-like; (), inhibitory/negative regulation has been shown; GPCR, G protein-coupled receptors.
MARKK is highly homologous to TAO-1 (thousand-and-one amino acid kinase) (46).
TABLE 2. Terminology and localization of mammalian
Par-1 family members
Synonymsa Subcellularlocalization
Par-1a, MARK3, C-TAK1, p78/KP78,
1600015G02Rik, A430080F22Rik,
Emk2, ETK-1, KIAA4230, mKIAA1860,
mKIAA4230, M80359............................................Basolateralb/apicalc
Par-1b, EMK, MARK2, AU024026,
mKIAA4207............................................................Basolateral
Par1c, MARK1...........................................................Basolateral
Par1d, MARK4, MARKL1.......................................Not asymmetricd
a Par should not to be confused with protease-activated receptor 1 (PAR1
29); C-TAK1, Cdc twenty-five C-associated kinase 1; MARK, microtubule
affinity regulating kinase; MARKL, MAP/microtubule affinity-regulating kinase-
like 1.
b Basolateral to a lesser degree than Par-1b (37).
c Human KP78 is asymmetrically localized to the apical surface of epithelial
cells (76).
d Variant that does not show asymmetric localization in epithelial cells when
overexpressed (95).
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//escore.im.wustl.edu). A total of 96 G418-resistant ES cell clones were analyzed
for homologous recombination by Southern blotting, and three clones were
found to be positive. Positive ES clones were karyotyped and microinjected into
3.5-day postcoitus (dpc) C57BL/6 blastocysts, which subsequently were
implanted into the uteri of pseudopregnant C57BL/6  C3HF1 foster mothers.
Male chimeras selected by the percentage of agouti color were mated to C57BL
/6 females. Germ line transmission was determined by agouti coat color. F1
animals were tested for the targeted Par-1a allele by Southern blotting and the
PCR analysis of tail DNA. Heterozygous (HET) F1 males/females were
interbred to generate the F2 littermates used for subsequent breeding and
analysis and are referred to as wild-type, heterozygous, and null pups/mice.
Western blotting. Tissues from wild-type and knockout animals were homog-
enized in 800 	l of mammalian cell lysis buffer (MCLB; 50 mM Tris-HCl, pH 8.0,
5 mM EDTA, 0.1 M NaCl, 0.5% NP-40, 2 mM dithiothreitol [DTT]) containing
1 	M microcystin, 1 mM sodium orthovanadate, 10 mM -glycerol phosphate, 1
mM sodium fluoride, 2 	M phenylmethylsulfonyl fluoride (PMSF), and protease
(Sigma, St. Louis, MO) and phosphatase inhibitor cocktails (Calbiochem, Gibbs-
town, NJ). Homogenates were rocked for 15 min at 4°C and then clarified twice
by centrifugation. Clarified lysates were resolved by SDS-PAGE on a 10% SDS
gel, and Western blotting was carried out with antibodies specific to actin (1:
4,000; Sigma Chemical Co.), tubulin (1:1,000; Sigma), -catenin (1:10,000; BD
Biosciences/Pharmagen), Par-1a ascitic fluid (1:10,000) (45), glycogen synthase
(1:1,000; Cell Signaling), phosphoglycogen synthase (1:1,000; Cell Signaling),
and LC-3 (1:1,000; Cell Signaling). Par-1b was detected with ascites generated
using a monoclonal antibody produced against keyhole limpet hemocyanin
(KLH)-conjugated peptide corresponding to amino acids 288 to 307 (PDYKD
PRRTELMVSMGYTRE) of human Par-1b. Bound primary antibodies were
detected with horseradish peroxidase (HRP)-conjugated goat anti-mouse anti-
body (Jackson, West Grove, PA), and proteins were visualized by chemilumi-
nescence.
Tissue distribution. The distribution of Par-1a and Par-1b in various tissues
was examined using a modified Western blot protocol. In brief, mouse tissues
harvested from 
6-month-old mice were homogenized in 0.8 ml of mammalian
cell lysis buffer (as described above). Lysates were rocked for 15 min at 4°C,
followed by centrifugation for 10 min at 20,800  g. Clarified supernatants were
transferred to prechilled tubes. Proteins were resolved by SDS-PAGE on 7.5%
gels until the 50-kDa molecular mass marker was at the bottom of the gel.
Proteins were transferred to nitrocellulose membranes in CAPS buffer [0.1 M
FIG. 1. Targeted disruption of Par-1a in mice and tissue distribution of Par-1a and Par-1b. (A) Par-1a locus (top), targeting vector (middle),
and chromosomal organization after recombination (bottom). The Par-1a gene was disrupted by the insertion of a neomycin (neo) phosphotrans-
ferase cDNA as a selectable marker. Sizes of upstream (2 kb) and downstream (3.8 kb) homologous arms are indicated (gray boxes), as is exon
2 (open box). Black boxes indicate positions of the probes for genomic Southern blotting; triangles depict locations of PCR primers for genotyping.
Abbreviations: P, PstI; B, BglII; S, SacI; Hp, HpaI; N, NcoI; H, HindIII. (B) Southern blot analysis demonstrating homologous recombination at
the Par-1a locus. Genomic DNA was digested with PstI and subjected to Southern blotting using the 5 and 3 probes indicated in panel A.
Genotypes are indicated (WT, wild-type mouse; HET, heterozygous; KO, homozygous). (C) PCR analysis of mouse DNA (tail), amplified with
three PCR primers (a, b, and c) shown in panel A. The WT allele produces a 300-bp PCR product, and null alleles produce a 400-bp PCR product.
(D) Western blot analysis of Par-1a protein in brain lysates prepared from C57BL/6-mice. (E) Tissues from wild-type, Par-1a/, and Par-1b/
mice were isolated. Protein lysates from the indicated tissues were resolved by SDS-PAGE and subjected to Western blotting for the indicated
proteins: brain (0.2 mg), brown adipose tissue (BAT; 1.1 mg), white adipose tissue (WAT; 1.1 mg), colon (0.4 mg), stomach (Stom; 0.4 mg), thymus
(Thym; 0.4 mg), testis (Test; 0.4 mg), spleen (SPLN; 0.4 mg), skeletal muscle (SKM; 0.4 mg), and liver (0.13 mg). W, wild type; K, knockout.
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3-(cyclohexylamino)-1-propanesulfonic acid and 10% methanol (C2632; Sigma,
St. Louis, MO)] at 1.2 mA for 1.5 h. Membranes were blocked in 1 TBST (100
mM Tris, pH 8.0, 1.5 M sodium chloride, 2% Tween 20) containing 5% milk for
1 h. Membranes were probed with Par-1a ascites (1:10,000), Par-1b ascites
(1:1,000), actin (1:4,000; Sigma Chemical Co.), or -catenin antibody (1:30,000)
by being rocked overnight at 4°C. Membranes were washed four times for 13 min
each in 1 TBST. Membranes then were incubated with a goat anti-mouse
antibody (dilution, 1:30,000; Jackson, West Grove, PA) for 1 h at room
temperature. Membranes then were washed four times in 1 TBST for 13
min each. Blots were developed using ECL detection reagent (GE Health-
care, Piscataway, NJ).
Breeding, animal weights, and growth measurements. Embryos and pups
generated from heterozygous crosses were weighed and genotyped by PCR
analysis. Plug observation was recorded as 0.5 dpc; embryos were harvested,
rinsed, and weighed. Mean body weights at each time point were compiled from
at least 6 mice per genotype. Breeding schemes followed standard protocols, and
for double-knockout (DKO) experiments genotypes are abbreviated by a two-
letter code (the first letter indicates Par-1b status, and the second letter indicates
Par-1a status: W, /; H, /; K, /; e.g., HK). Binning and comparison
within and between genotypes via univariate and multivariate analyses tested
trends over time. We assessed the number and genotype of litters in 10 super-
ovulated timed pregnancies at 8.5 and 10.5 dpc. Offspring ratios for Par-1a/,
Par-1b/, and all genotypes in DKO experiments were recorded as pups/litter
and total numbers per genotype. The significance of deviations from expected
Mendelian ratios were tested using chi-square statistics with 2 (WT, HET, and
KO) or 8 degrees of freedom (KK, WW, WK, KW, WH, HW, KH, HK, and HH)
in Par-1a null and DKO experiments, respectively (two-tailed P values are pro-
vided).
Metabolic measurements (indirect calorimetry). Metabolic measurements
were determined using previously established protocols (8, 43). Briefly, meta-
bolic characterization included metabolic rate, energy expenditure, activity, food
consumption (in g/day), and body temperature. During data analysis, energy
expenditure and metabolic rate were normalized with respect to body weight.
Energy expenditure and respiratory quotient (RQ) were calculated from the gas
exchange data. RQ was the ratio of the rate of the elimination of carbon dioxide
(VCO2) to VO2 and the equation for energy expenditure (or heat) was (3.815 
1.232  RQ)  VO2. Activity was measured on x and z axes using infrared
photobeams to count the number of beam breaks.
HFD studies. HFD studies followed previously published protocols (43) and
consisted of a total of 55 mice. In 35 3-week-old mice (WT, Par-1a/, Par-1b/),
the regular rodent chow diet (CD) was replaced with an adjusted-calories diet
(42% fat) from Harlan Teklad (88137; Western diet; Madison, WI). The weight
of the HFD chow was recorded, and food consumption as well as mouse weight
were determined for individual mice on a weekly basis. Although resistance to
weight gain on HFD has been reported previously for Par-1b null mice (43), for
the direct comparison and determination of specific organ uptake values, the
HFD experiment included a new group of nine Par-1b null mice and therefore
consisted of six different trial groups: WT-CD, WT-HFD, Par-1a/-CD, Par-
1a/-HFD, Par-1b/-CD, and Par-1b/-HFD. Metabolic profiling after a
total diet time of 16 weeks consisted of (i) fasting (n  18 CD, 35 HFD) and
blood glucose levels after feeding (n  6 per genotype, randomly selected), (ii)
glucose tolerance testing (GTT) of 18 CD mice (6 per genotype, randomly
selected) and all HFD mice, (iii) fludeoxyglucose ([18F]FDG) biodistribution
experiments (n  19 CD, 31 HFD), (iv) organ weights, and (v) histologic exam-
ination. The HFD trial was designed to allow at least 24 h between GTT and
[18F]FDG biodistribution studies, during which animals were kept on HFD.
Serum factor quantification. Serum levels of insulin, triglycerides, adiponec-
tin, leptin, and cholesterol were determined by Ani Lytics Incorporated (Gaith-
ersburg, MD; n 11 animals per genotype and sex); glucagon and free fatty acids
were determined according to previously established protocols (18).
Glucose and insulin measurements and tolerance tests. Randomly fed or
fasted mice were analyzed, and blood glucose levels were determined using a
-glucose photometer and -glucose cuvettes (HemoCue AB, Angelholm, Swe-
den) or Accucheck advantage glucometer (Roche Diagnostics Corp., Indianap-
olis, IN). Normoglycemia was defined as blood glucose values between 90 to 130
mg/dl. Intraperitoneal (i.p.) glucose tolerance tests were performed on fasted (12
h) animals on CD and all HFD trial mice. Mice were injected i.p. with D-glucose
(20% solution; 1 g/kg of body weight), and blood glucose levels were determined
at 15, 30, 60, 90, 120 min, and24 h postinjection. In addition, insulin levels were
determined during GTT immediately before and 15, 30, and 60 min after glucose
injection. Therefore, 
20 to 30 	l of blood was collected using the Microvette
200 capillary blood collection system (Sarstedt, Newton, NC) and centrifuged at
30,000  g for 5 min. Fasting serum insulin levels were determined for 50 male
mice on CD (n  24 WT, 8 Par-1a/, 18 Par-1b/) and 18 randomly selected
mice on HFD (n  6 per genotype) using rat insulin as a standard and enzyme-
linked immunosorbent assays (ELISA) as specified by the manufacturer (Crystal
Chem, Inc., IL). Insulin tolerance tests (ITT) were performed on 6-h-fasted male
mice (n  9 Par-1a/, 9 Par-1a/). Insulin sensitivity in Par-1b null mice has
been reported (43) and was not repeated. Blood glucose values were mea-
sured immediately before and at 15-min intervals for a total of 90 min after
the i.p. injection of insulin (0.30 IU/kg HumulinR; Eli Lilly and Company,
Indianapolis, IN).
MicroPET studies. Micro-positron emission tomography (microPET) studies
entailed the imaging of cohorts of male WT and Par-1a null mice that were
repetitively imaged once a week for four consecutive weeks, each time under a
different metabolic condition. Brown adipose tissue (BAT), skeletal muscle
(SM), heart, liver, and brain were examined under the following four conditions:
(i) fasted with saline, (ii) fasted with insulin, (iii) nonfasted with saline, or (iv)
nonfasted with insulin. The next morning, either 0.5 U/kg insulin (Humulin N;
Eli Lilly, Indianapolis, IN) or saline was administered to mice by i.p. injection.
Thirty minutes after the injection, mice were lightly anesthetized with isoflurane,
followed by a tail vein injection of [18F]FDG (
200 to 500 	Ci in saline).
Immediately after the injection of radiotracer, mice were placed supine in the
microPET scanner (Focus120 or Focus220 scanner; Concorde MicroSystems,
Knoxville, TN) and imaged (acquisition time, 
10 min; one bed position; or-
dered set expectation maximum reconstruction). Mice were allowed to recover
and then were anesthetized and imaged again at 1 and 2 h after the injection of
radiotracer. The Par-1b null and WT mice used for comparison were age-
matched males and treated as described above, except that they were imaged on
an R4 scanner (43). MicroPET images were corrected for decay, but not atten-
uation or scatter, and then stacked regions of interest (ROI) of relevant tissues
and organs were analyzed with AnalyzePC 6.0 software. ROI counts were con-
verted to counts per gram of tissue (nCi/g), assuming a tissue density of 1 g/ml.
Data for the accumulation of [18F]FDG on microPET images were expressed as
standard uptake values (SUV), representing counts per gram of tissue divided by
the injected dose of radioactivity per gram of animal weight (87, 88). After
statistical analysis using a one-way analysis of variance (ANOVA) and Student’s
t tests, comparison between genotypes and experiments was enabled by the
normalization of the SUV to the corresponding WT littermates, with data for
Par-1a- and Par-1b-disrupted mice against their littermate WT as the normalized
average SUV  standard errors of the means (SEM); errors were propagated
(see below).
[18F]FDG biodistribution experiments. As previously reported, white adipose
tissue (WAT) cannot be analyzed by noninvasive microPET imaging (43). As an
alternative, we examined the glucose uptake of WAT and other organs by
traditional [18F]FDG biodistribution (12, 20, 53, 88). Mice were anesthetized
with isoflurane (2% vaporized in oxygen), followed by the tail vein injection of
[18F]FDG (20 	Ci in 100 	l saline). Sixty minutes after [18F]FDG injections,
mice were sacrificed by cervical dislocation (under anesthesia). Blood, liver,
heart, brain, muscle, WAT, and BAT were rapidly removed and weighed, and
their radioactivity was measured using a Beckman 8000 gamma counter. The
percent injected dose per gram of tissue (% ID/g) was calculated [(tissue 	Ci)
(injected Ci)1 (g tissue)1  100] and subsequently compared among tissues,
genotypes, and diets. Biodistribution analysis was performed on 31 HFD mice
(17 WT, 8 Par-1a/, 6 Par-1b/) and 19 mice from the CD arm (age-matched
control group; total n  50). Tissue samples from these mice were fresh-frozen
and stored at 80°C. Subsequent cryostat sections confirmed tissues and allowed
histomorphological/histochemical comparison to tissues obtained from animals
that did not undergo [18F]FDG uptake (n  5; no differences observed) or HFD
(see Results). For these HFD trial biodistribution experiments, the 50 mice were
prospectively assigned to one of nine experimental days with an average of six
animals per experiment (range, 3 to 10 mice/day). Excluding the 16 weeks on
HFD (as described above), these experiments were performed during a 10-
month period.
Starvation experiments. Starvation experiments consisted of the determina-
tion of blood glucose as well as ketone levels using a MediSense Precision Xtra
diabetes glucose and ketone monitor system (Abbott, Alameda, CA). After
overnight fasting (20 h), measurements were repeated; one group of mice was
subjected to extended fasting (an additional 4 h), and the other group of mice
was given an i.p. injection of 2 mg/g glucose for 2 h. Tissues were collected at all
time points and samples separated for Western blotting, routine histology, elec-
tron microscopy (EM), and glycogen determination.
Dissection and histology. Organs were excised, weighed, rinsed in phosphate-
buffered saline (PBS), fixed in 10% neutral-buffered formalin, rinsed in PBS, and
stored in 70% ethanol. Formalin-fixed tissues were paraffin embedded (FFPE)
and sectioned (
5 	m) using standard procedures. For morphological evalua-
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tion and fat content, hematoxylin-and-eosin (H&E) and oil red O staining was
performed on FFPE and fresh-frozen sections (stored at 80°C), respectively.
Morphological analysis was performed using multiple independent samples per
site/organ (13 to 26 samples per genotype) as well as all 55 animals in the HFD
trial. We quantified BAT and WAT samples taken from the interscapular and
gonadal fat pads, respectively. Quantification was performed using digital image
processing via ImageJ (v. 1.37; http://rsb.info.nih.gov/ij/) and Photoshop CS3
(Adobe Systems) according to previously established semiautomatic protocols
(16, 39). Specifically, oil red O positivity was quantified from 20 high-power
fields, cell numbers or lipid vacuoles were quantified in 6 to 20 randomly chosen
images per sample, and periodic acid Schiff (PAS) staining was quantified using
integrated density measurements (IntDen; equivalent to the product of the area
and mean gray value, with gray value being the luminescence value between 0
[black] and 255 [white]).
Glycogen determination. Fifty milligrams of liver and skeletal muscle samples
were extracted with 0.9 N perchloric acid and 99% ethanol to precipitate glyco-
gen. The glycogen from the pellet was dialyzed and digested to free glucose with
amyloglucosidase. Glucose concentrations were measured by the glucose oxidase
method (glucose analyzer II; Beckman Instruments, Fullerton, CA).
EM. EM was performed according to established protocols (85). Tissues were
fixed overnight at 4°C in modified Karnovsky’s fixative containing 3% glutaral-
dehyde and 1% paraformaldehyde in sodium cacodylate buffer, pH 7.4. After
being rinsed in sodium cacodylate buffer, samples were postfixed in phosphate
cacodylate-buffered 21% OsO4 for 1 h, dehydrated in graded ethanols with a
final dehydration in propylene oxide, and embedded in Embed-812 (Electron
Microscopy Sciences, Hatfield, PA). One-micron-thick plastic sections were ex-
amined by light microscopy after being stained with toluidine blue. Ultrathin
sections (90 nm thick) of individual samples were cut onto formvar-coated slot
grids, which permit the visualization of larger cross-sections. Sections were post-
stained with uranyl acetate and Venable’s lead citrate and viewed with a JEOL
model 1200EX electron microscope (JEOL, Tokyo, Japan). Digital images were
acquired using the AMT advantage HR (Advanced Microscopy Techniques,
Danvers, MA). Plastic sections as well as an ultrastructural review were per-
formed blinded to the genotype.
Digitization and image analysis. Analyses were performed using an Olympus
DP70 digital camera (Olympus, Tokyo, Japan) connected to an Olympus BX51
light microscope or a Scanscope XT whole-slide scanner/ImageScope
v10.0.36.1805 (Aperio, Vista, CA). Image and pixel quantification employed
established semiautomatic threshold algorithms (60) using the software package
ImageJ (http://rsb.info.nih.gov/ij) (1). Statistical testing between groups was per-
formed using Student’s t test and the Wilcoxon two-sample test.
Statistics. Chi-squared t tests (two-tailed), the nonparametric alternative
Mann-Whitney U test, one-way and two-way ANOVA, and Bonferroni posttests
to compare replicate means were used when appropriate. In experiments with
small numbers of samples (defined as n  12), the D’Agostino-Pearson omnibus
K2 normality test (24) was used to approximate the Gaussian distribution of
values. P values of 0.05 indicate non-Gaussian distribution, and we assessed
these experiments with both parametric and nonparametric tests; both P values
are provided when applicable. In all studies, the accepted level of significance
was P  0.05, and data are reported as means  SEM. In selected experiments
and for comparison between strains and experiments, values were normalized to
the corresponding WT and errors were propagated according to the formula
xWT/xWT)2  (xKO/xKO)2 ]1/2  xNKO, where  is the SEM, x is the average, and
N is the normalized average. N KO was adapted from reference 66.
Error propagation and statistical tests in general were chosen assuming the
most pessimistic situation (80). All data were analyzed using Prism 5.0b (Graph-
Pad Software Inc., La Jolla, CA) or Microsoft Excel 2008 (version 12.1.9; Mi-
crosoft Corporation, Redmond WA).
RESULTS
Gene targeting was employed to determine the conse-
quences of Par-1a loss in mice (Fig. 1A). The targeted Par-1a
allele was introduced by electroporation into RW4 embryonic
stem (ES) cells derived from the mouse strain 129X1/
SvJ. Southern blot analysis identified correct targeting events
(Fig. 1B). Southern blotting and PCR analysis demonstrated
that the agouti offspring produced by the chimeric males were
heterozygous for the Par-1a locus (data not shown). F1 het-
erozygous offspring were intercrossed, and F2 offspring were
genotyped by PCR (Fig. 1C). Western blotting demonstrated
that the targeted disruption of Par-1a produced a null allele of
the locus (Fig. 1D), and multitissue Western blotting con-
firmed the ablation of Par-1a/b in all tissues of the correspond-
ing null-mice (Fig. 1E).
Higher levels of Par-1a were noted in several tissues of
Par-1b null mice, including brain, BAT, thymus, and muscle
(Fig. 1E, lanes 2, 5, 17, and 26), which may provide an expla-
nation for Par-1a compensation of Par-1b loss (see below).
However, increased Par-1b levels were not observed in Par-1a
null tissues. Also observed in Fig. 1E is the differential expres-
sion of Par-1a splice variants in various mouse tissues. The
NCBI database contains five Par-1a splice variants with their
respective protein products, ranging from 659 to 753 amino
acids. It is not known whether functions differ among the
various splice variants.
Par-1a/ mice are hypermetabolic and show 9% reduction
in body weight. When Par-1a heterozygotes were intercrossed,
the offspring contained WT, HET, and KO pups, although
genotype proportions deviated significantly from expected
Mendelian ratios with the loss of homozygous KO mice (n 
750; WT, 30%; HET, 52%; KO, 17%; 2  27.864, P 
0.0001). All pups developed without any visible dysmorphisms
or obvious external pathology, and animals survived to adult-
hood. Par-1a null mice exhibited significant weight differences
compared to their wild-type littermates (e.g., at 32 weeks, WT
mice [n  6] were 33.4  0.94 g and Par-1a/ mice [n  6]
were 25.5  0.42 g; P  0.0001, t test). In contrast to Par-1b
null mice that show reduced weights at 6 weeks of age (9, 42),
in Par-1a null mice the difference was not discernible this early
(Fig. 2A and B).
Body weight represents a net balance of food intake and
energy expenditure. Based on the decreased weight in Par-1a
null mice, we measured total energy expenditure (EE), total
metabolic rate (MR), and respiratory quotients of male mice
on a regular chow diet. Par-1a null mice exhibited higher O2
consumption (MR showed an 
9% increase) (Fig. 2C) and
higher EE (10% increase) (Fig. 2D). We also analyzed the
respiratory quotient (RQ  VCO2/VO2) as a measure of fuel-
partitioning patterns, and RQ ranged from 0.76 to 0.78 (P 
0.32, t test) (Fig. 2E). Food intake in Par-1a null mice was
slightly less than that of WT littermates, although this differ-
ence was not statistically significant (WT, 3.15  0.09; Par-
1a/, 2.94  0.04; P  0.16, t test) (Fig. 2F). Thus, unlike
Par-1b null mice, Par-1a null mice are not hyperphagic (43).
The lack of effect on RQ suggests that there was no difference
in fuel selection between carbohydrates and lipids, leading us
to explore whether the increase in energy expenditure occurs
secondarily to increased thermogenesis. However, body tem-
peratures of Par-1a null mice were similar to those of WT
littermates (WT, 34.3  0.5; Par-1a/, 34.1  0.8; P  0.8, t
test), and the expression of uncoupling proteins in selected
tissues showed no significant difference (not shown). Lastly,
Par-1a null mice showed similar levels of activity (compared to
that of WT mice; P  0.96), and basic sensorimotor testing as
well as open-field tests showed no significant difference (P 
0.64 [not shown]).
Par-1a/ mice are normoglycemic and normoinsulinemic
and show no insulin sensitivity. Serum levels of insulin, glu-
cagon, leptin, adiponectin, triglycerides, cholesterol, and free
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fatty acids in Par-1a null mice were measured and compared to
values from WT and Par-1b null mice (20-week-old mice on
regular chow diet) (Table 3). Male Par-1a null mice exhibited
levels of adiponectin that were 1.6-fold higher than those of
WT littermates. Par-1b null mice showed a significant decrease
in female adiponectin values. In contrast to Par-1b null mice,
Par-1a null mice showed no difference in serum insulin levels
(Table 3), and blood glucose was normal (WT, 152  18 mg/dl;
Par-1a/, 147  5 mg/dl; P  0.216, t test). Par-1a null mice
on CD exhibited ITT curves identical to those of WT litter-
mates (Fig. 2G; P  0.87, one-way ANOVA). On CD, Par-1a
null mice showed no significant difference in GTT relative to
that of WT littermates (Fig. 3C) (P  0.15, t test; and P 
0.181, two-way ANOVA for the entire time course; Par-1b/
data not shown).
Par-1a/ mice show delayed weight gain on high-fat diet.
The striking resistance to HFD-induced weight gain in Par-1b
null mice (43) prompted us to challenge Par-1a null mice with
FIG. 2. Par-1a/ mice are growth retarded and hypermetabolic. (A) Body weights of mice from birth to 30 weeks of age (n  4 to 14 per
genotype per time point). (B) Body weights at 6 and 20 weeks. Body weights of Par-1a/, Par-1a/, and Par-1a / mice at 6 weeks of age are
shown (number of animals per sex indicated). Also shown are metabolic rate (C), energy expenditure (D), respiratory quotients (RQ 
VCO2/VO2) (E), and food intake (F) in WT and Par-1a null mice. (G) Insulin tolerance tests were performed by the i.p. injection of 0.30 U/kg
insulin into WT and Par-1a/ mice; tail bleeds were obtained and glucose levels were monitored at the indicated time points. Glucose levels were
plotted as percent blood glucose at time zero before injection.
TABLE 3. Metabolic characteristics of WT, Par-1a/, and Par-1b/ animalsa
Animal typed Insulin(ng/ml)
Glucagon
(pg/ml)
Leptin
(ng/ml)
Adiponectin (	g/ml) Triglyceride
(mg/dl)
Cholesterol
(mg/dl)
NEFAc
(	mol/liter)Male Female
WT 0.65  0.10 45.5  11.7 3.68  0.26 9.8  0.66b 17.9  1.7 74.9  3.46 83.27  2.4 1,303  65.8
Par-1a/ 0.61  0.08 31  4.33 3.64  0.16 16.5  1.6 18.4  2.2 73.1  3.77 74.95  2.87 1,329  107
Par-1b/ 0.37  0.04 34  2.25 3.02  0.16 11.4  1.3 11.7  0.84 62.2  3.39 73.45  2.81 1,149  66.3
a Twenty-week-old mice on a regular chow diet were fasted overnight (n  11 per genotype, all male unless otherwise indicated); serum values are expressed as the
means  SEM of measurements obtained.
b Male mice had significantly lower adiponectin levels (P  0.0003). Note that this gender difference is lost in both Par-1 mice.
c NEFA, nonesterified fatty acids.
d P values were determined by Student’s t tests comparing Par-1 mice to the WT. P values for WT and Par-1a/ mice were the following: insulin, 0.74; glucagon,
0.27; leptin, 0.79; adiponectin (male), 0.0008; adiponectin (female), 0.87; triglyceride, 0.74; cholesterol, 0.03; NEFA, 0.84. Values for adiponectin (male) and cholesterol
were significant. P values for Par-1b/ mice were the following: insulin, 0.04; glucagon, 0.39; leptin, 0.16; adiponectin (male), 0.28; adiponectin (female), 0.005;
triglyceride, 0.013; cholesterol, 0.011; NEFA, 0.11. Values for adiponectin (female), triglyceride, and cholesterol were significant.
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a similar HFD for 16 weeks (Fig. 3A and B). The main finding
was the reduced weight gain of Par-1a null mice compared to
that of WT littermates on HFD (Fig. 3A). Specifically, while
Par-1b null mice on HFD showed a statistically significant lack
of weight gain after 7 weeks [designated t(7w); t(7w)  3.297;
P  0.05; t(17w)  7.234; P  0.001, two-way ANOVA with
Bonferroni posttests; weight gain, 5%; weight on CD, 19 
0.75 g; weight on HFD, 20.3  1.34; P  0.4097, t test], Par-1a
null mice on HFD continued to gain weight during the entire
experiment (Par-1a/ weight gain, 39%; CD weight,
23.47  1.6 g; HFD weight, 32.4  1.47; P  0.004, t test),
albeit at a reduced rate and significantly different from that of
WT littermates (70% weight gain; CD weight, 27.12  0.5 g;
HFD weight, 46  0.9; P  0.001, t test). HFD food intake of
Par-1a null mice was similar to that of WT littermates (P 
0.39, t test). While the Par-1a phenotype with a reduced rate of
weight gain is, at first glance, less dramatic than that observed
in Par-1b null mice [Par-1a/ versus WT: t(all)  2.779, P 
0.05, one-way ANOVA with Bonferroni’s multiple comparison
test], it is a highly significant finding (P  0.001) (Fig. 3B).
Par-1a null mice required 7 additional weeks of HFD to reach
the original weight of their WT littermates.
Par-1a/ mice show resistance to glucose intolerance on
high-fat diet. Par-1a null mice fed an HFD were subjected to
glucose tolerance testing (Fig. 3C). As expected, WT mice on
HFD exhibited glucose intolerance relative to that of WT mice
on CD, with a prolonged elevation of blood glucose of 
400%
from 15 min onwards (t value  3.645, P  0.01, two-way
ANOVA). Strikingly, Par-1a null mice exhibited improved glu-
cose tolerance on HFD relative to that of WT controls on the
same diet (P 0.041, t test [two genotypes]; t value 3.38, P
0.01, one-way ANOVA [all genotypes]) (Fig. 3D). GTT re-
sponse in Par-1a null mice under HFD conditions was essen-
tially identical to that of WT and Par-1a null mice on CD (P 
0.4781, t test [two genotypes]; t value  0.346, P  0.05,
one-way ANOVA [all genotypes]) (Fig. 3D and data not
shown). We conclude that Par-1a disruption leads to the main-
tenance of normal glucose tolerance even under HFD condi-
tions; accordingly, Par-1a null mice on HFD were normogly-
cemic (P  0.3, t test). We next examined serum insulin levels
in HFD-fed mice during the first 60 min of the GTT (Fig. 3D)
and found significantly lower levels in Par-1a null mice (t
value  3.16, P  0.0194, t test [two genotypes]; F [mean
square between groups over the mean square within groups] 
6.454, P  0.018, one-way ANOVA). Although we did not
formally assess insulin tolerance in Par-1a null mice on HFD,
the combination of improved glucose tolerance and reduced
insulin secretion during the GTT is indicative of peripheral
insulin hypersensitivity. Thus, Par-1a null mice demonstrate
normal insulin and glucose sensitivity unless challenged by
HFD. In contrast, Par-1b null mice exhibited insulin hypersen-
sitivity even on CD (43). The direct assessment of pancreatic
islets has proven difficult with Par-1 mice (38); however, mor-
phological and morphometric differences were not observed in
the islet organ of Par-1a null mice (not shown).
Par-1a/ mice show diet-dependent reduced adiposity. We
determined whether the reduced body weight of Par-1a null
mice was reflected disproportionately in different tissues (Fig.
4A). Measurements of tissue weights in Par-1a null mice indi-
cated that decreased weights of most organs were proportional
to total body weight and consistent with a decrease in overall
body mass rather than in specific organs. However, two tissues
did not follow this rule and were disproportionately smaller:
white adipose tissue (WAT from gonadal fat pads) and brown
adipose tissue (BAT). We also performed the dissection of
tissues in the mice on HFD and, as expected, the energy excess
in WT mice led to a disproportionate increase in overall adi-
posity (BAT-CD versus BAT-HFD, P  0.001; WAT-CD ver-
sus WAT-HFD, P 2.5e5; t tests) (Fig. 4A). Par-1a null mice
showed a similar disproportionate increase in overall adiposity
(BAT-CD versus BAT-HFD, P  0.007; WAT-CD versus
WAT-HFD, P  1.4e9; t tests) with a weight increase in BAT
and gonadal WAT that eliminated the reduced adiposity ob-
served under chow diet (Fig. 4A, columns a versus b and c
versus d, both P  0.08, t tests).
The dissection of the gonadal fat pads (Fig. 4B) represen-
tative of the WAT showed a disproportionate decrease in the
fat mass of Par-1a null mice relative to that of WT mice on CD
(Fig. 4C; raw weight values provided). The weight difference
FIG. 3. Resistance of Par-1a/ mice to high-fat diet-induced met-
abolic changes. (A) Body weights during 15 weeks of HFD starting at
3 weeks of age in male mice (*, P  0.001; **, P  0.005). (B) Body
weight gain (as percentages) indicated above weight comparisons of
the control group (black/white/gray) and the HFD arm of the trial
(red) in 18-week-old male mice. (C) Glucose tolerance testing was
performed by the i.p. injection of D-glucose at 1 mg/g body weight into
all genotypes on chow and high-fat diet. Glucose levels were monitored
as indicated and expressed in percentages of initial glucose normalized
to their littermates on chow; for comparison, a dotted band shows the
time course for WT and Par-1a/ mice on chow diet. Statistical
testing was performed using original values, and P values are provided
for testing between genotypes on HFD and between WT-HFD and
WT-CD, when significant. (D) Serum insulin levels as determined
by ELISA for the first four time points of the glucose tolerance test
after HFD.
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corresponds to 
48% (Par-1a/) and 
36% (Par-1b/) of
the WT-WAT weight (Fig. 4C). Although we did not quanti-
tatively assess abdominal fat, during dissection the dimensions
of mesenteric root, omental, and retroperitoneal fat content
were strikingly lower in Par-1a null mice, and this difference is
not accounted for in the displayed values of gonadal WAT
(Fig. 4C).
The dissection of the interscapular fat depot, representative
of BAT, is shown in Fig. 4E. The weight difference corresponds
to 
52% (Par-1a/) and 
38% (Par-1b/) of the WT-BAT
weigh (Fig. 4F). For both adipose tissues, the difference sig-
nificantly exceeded the overall 
9% weight difference ob-
served in Par-1a null mice. Adipocyte counts from six indepen-
dent samples of WAT and BAT indicated no differences in
adipocyte size from WT and Par-1a null mice (for WAT, WT
mice showed 436  100 adipocytes per mm2 and Par-1a/
mice showed 419  74; P  0.137, t test; for BAT, WT mice
showed 1,894  349 and Par-1a/ mice showed 1,385  434;
P  0.382, t test). Thus, we conclude that the observed de-
crease in the adipose tissue of Par-1a null mice is due to
decreases in total adipocyte cell number, not cell size, findings
similar to those made for Par-1b null mice (43).
FIG. 4. Reduced adiposity and decreased glucose uptake in Par1a/ mice. (A) Tissue weights normalized to total body weight in the indicated
tissues from 18-week-old male WT and Par-1a/ mice fed chow diet (black) or HFD (red; selected tissues); n  7 samples per tissue. For an
explanation of labels a to e, see Results. (B) Hematoxylin and eosin (H&E) stain of WAT from Par-1a/ and Par-1a/ mice; insets, gonadal fat
pads. (C) Weight comparisons of WAT between WT, Par-1a/, and Par-1b/ mice on chow (black) and after 16 weeks of high-fat diet (red);
weights were normalized to that of the WT on a chow diet. Statistical tests and indicated P values derived from original weights (provided below
bars). (D) Invasive biodistribution experiments following the injection of [18F]FDG and the dissection of gonadal WAT 1 h postinjection; values
are expressed as the percentage of injected dose per gram of tissue (%ID/g). (E) H&E stain of BAT from Par-1a/ and Par-1a/ mice; insets,
interscapular fat pads. (F) Weight comparisons of BAT between WT, Par-1a/, and Par-1b/ mice on CD (black) and after 16 weeks of a high-fat
diet (red); weights were normalized to that of the WT on a chow diet. Statistical tests and indicated P values derived from original weights
(provided below bars). (G) Representative coronal section microPET images of [18F]FDG uptake in Par-1a/ (top) and Par-1b/ mice (bottom)
1 h after [18F]FDG injection.
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We also determined the weight of muscle samples (tibialis
anterior, gastrocnemius, plantaris, diaphragm, and extensor
digitorum longus) typically used for the assessment of myo-
genic phenotypes and fiber type composition (22, 84), which,
under HFD conditions, showed significantly decreased weights
(WT, P  3.7e6; Par-1/, P  0.006; both t tests) (Fig. 4A,
column e). Skeletal muscle plays an integral role in the coor-
dination of fuel homeostasis (41) and is the most important site
of insulin-stimulated glucose disposal (26). We therefore per-
formed functional (motor, biodistribution, and microPET
analysis), biochemical (glycogen quantification), and morpho-
logical (routine, PAS, fiber type analysis, and ultrastructure)
screening of skeletal muscle but observed no differences be-
tween wild-type and Par-1a null mice (not shown). Thus, the
reduced body weight of Par-1a mice on HFD likely is ac-
counted for by a combination of reduced muscle mass (3, 92)
and reduced adiposity, although the latter is not reflected in
the gonadal WAT measurements (Fig. 4A, columns c and d).
Par-1a loss causes decreased WAT glucose uptake in the
absence of BAT phenotype. MicroPET imaging of WAT was
performed (not shown); however, the reduced size of Par-1
null mice and high tracer concentrations in kidneys, bladder,
and skeletal muscle precluded the meaningful quantification of
uptake in retroperitoneal, gonadal, and calf fat deposits, re-
spectively. We therefore applied invasive biodistribution anal-
ysis, and in contrast to Par-1b null mice, WAT of Par-1a null
mice showed significantly decreased glucose uptake under nor-
mal dietary conditions (WT, 0.52  0.08%ID/g [n  9]; Par-
1a/, 0.32  0.05%ID/g [n  8]; U [sum of signed ranks] 
14; P  0.036, Mann-Whitney U test; P  0.05, t test) (Fig.
4D). When challenged with HFD, Par-1a null mice showed a
statistically significant increase in [18F]FDG uptake compared
to that of Par-1a null mice on chow diet that eliminated the
difference of glucose uptake from that of WT mice on HFD
(Fig. 4D).
We next examined glucose uptake in BAT of CD-fed Par-1a
null mice by microPET analyses of the interscapular BAT (Fig.
4G). We evaluated four different conditions at 1 h after
[18F]FDG injection: the fed and fasted state using acute insulin
challenge versus saline administration. As part of the HFD
trial, we also examined BAT glucose uptake via biodistribution
analysis in all genotypes. We found that the loss of Par-1a did
not significantly alter BAT glucose uptake in any of these six
tested conditions (not shown).
Although Par-1a null mice exhibited reduced fat mass on
chow diet and delayed weight gain relative to that of WT mice
on HFD, sampled gonadal adipose mass in Par-1a null mice
was not significantly different from that of WT mice after 16
weeks of HFD conditions (P  0.12 and 0.13, both t tests; for
WAT/BAT, n  8 Par-1a/ mice and 17 WT mice) (Fig. 4C
and F). In contrast, the BAT/WAT mass in Par-1b null mice
remained reduced under HFD conditions compared to that of
WT mice on the same diet (P  0.002 and 0.04, t tests [WAT/
BAT]; n  6 for Par-1b/ and 17 for WT) (Fig. 4C and F).
Par-1a/ mice show resistance to hepatic steatosis. The
chronic exposure of mice to HFD causes liver injury via the
accumulation of lipids, leading to fatty liver (steatosis) (13, 79).
The absence of steatosis in Par-1a null mice was apparent from
the gross examination of the liver, which was notably darker
than that of the WT littermates (not shown), and histologic
examination showed abundant panlobular, macrovesicular ste-
atosis in WT (Fig. 5A, image b, inset) but not Par-1a null livers
(Fig. 5A, image d). Remarkably, with respect to hepatic ste-
atosis, Par-1a null mice on HFD were no different than WT
mice on CD (Fig. 5A, compare image d to image a). Based on
previous findings (43), we quantified hepatic lipid content in
fresh-frozen sections stained with oil red O and found 14.6 to
25% in WT versus 6.4 to 7.7% in Par-1a null mice when
expressed as percent fat per high-power field (Fig. 5B). The
quantitative difference in the WT on chow diet (Fig. 5B) cor-
responds to an absence of centrilobular (zone III) lipid accen-
tuation in Par-1a null mice (Fig. 5A, compare image a to image
c). In addition, biodistribution studies demonstrated identical
[18F]FDG uptake in livers of Par-1a null and WT mice on CD
and HFD (not shown). Similarly, the microPET examination
of the liver using four different metabolic conditions (see Ma-
terials and Methods) did not show significant differences (P
value range, 0.12 to 0.71; t tests). These findings indicate that
Par-1a null mice show resistance to steatosis in the absence of
altered hepatic glucose uptake under both normal and HFD
conditions.
Decreased glycogen deposition in Par-1a/ livers leads to
hypoketotic hypoglycemia. The storage and utilization of glu-
cose is one of the main contributors to the pathophysiologic
changes in diabetes (21, 90). PAS staining was used to detect
glycogen content (Fig. 5C). Fasted WT liver showed partially
depleted liver glycogen stores (Fig. 5C, image a), whereas liver
sections from fasted Par-1a null mice exhibited the complete
depletion of hepatic glycogen content (PAS quantification
[fasted]: WT, 23.6  8.5; Par-1a/, 0.17  0.13; P  0.01, t
test) (Fig. 5C, image c). This depletion was not observed in
Par-1b null mice (26.68  2.8; P  0.73, t test) (Fig. 5C, image
e). Two hours after glucose administration, glycogen levels
were substantially elevated and visible and confluently PAS
positive in livers of WT mice (Fig. 5C, image b). In contrast,
Par-1a null mice showed the absence of the restoration of
hepatic glycogen content with only spotty PAS-positive islands
(Fig. 5C, image d). The quantitative enzymatic analysis of
glycogen was consistent with the PAS staining such that fasted
and glucose-stimulated liver glycogen was significantly de-
creased in Par-1a null animals (Fig. 5E) with no significant
difference in Par-1b null mice. After mice were fed, glycogen
levels were normal and no significant histological differences
were observed between groups (not shown).
To test the physiologic significance of hepatic glycogen de-
pletion in Par-1a null mice, we performed an extended fasting
experiment and observed significantly decreased glucose levels
in Par-1a null mice after overnight fasting (20 h) compared to
that of WT littermates (Fig. 5D). After four additional hours
without external energy sources, Par-1a null animal blood glu-
cose levels further declined (P  0.04 compared to results for
the WT mice; t test), and the mice developed hypoketotic
hypoglycemia (Fig. 5D). In contrast, Par-1b null mice showed
an absence of physiologic decline of blood glucose levels with
appropriately low ketone levels (Fig. 5D).
To test whether the tissue differences in glycogen levels
relate to glycogen synthesis, we determined total and phospho-
glycogen synthase (pGS) levels (Fig. 5F) and found increased
levels of GS and pGS in the livers of Par-1a null mice. Since
Par-1a null mice demonstrate resistance to steatosis as well as
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FIG. 5. Liver findings in high-fat diet and starvation experiments. (A) Morphological comparison of oil red O-stained sections shows resistance
to hepatic steatosis in Par-1a/ mice. The inset shows abundant macrovesicular steatosis. (B) Semiautomated pixel quantification, expressed as
the percentage of oil red O-positive structures (fat) per high-power field (HPF); genotypes, numbers of animals, and diet are indicated.
(C) Periodic acid Schiff (PAS) staining of liver of 20-week-old WT, Par-1a/, and Par-1b/ littermates following overnight fasting or 2 h after
the administration of 2 mg/g glucose by i.p. injection. Images are representative of 96 fields from eight animals. (D) WT mice show a physiologic
decrease in blood glucose in response to overnight starvation, with a nadir at the extended fasting time point (20  4 h [top]) and corresponding
increased ketone production (bottom); note the restoration of blood glucose and ketones 2 h after intraperitoneal glucose injection (2 mg/g).
Par-1a/ mice show significantly lower blood glucose levels at both time points with associated hypoglycemia at 20  4 h. Fasting hypoglycemia
is accompanied by a significant decrease in ketone levels (hypoketotic hypoglycemia). Par-1b/ mice maintained glucose levels and exhibited
expected lower ketone levels. (E) Glycogen content was measured in livers from 20-week-old Par-1a/, Par-1b/, and WT littermates following
overnight fasting or 2 h after the i.p. injection of 2 mg/g glucose. Tissues were extracted and acid hydrolyzed, and glycosyl units were assayed using
an amyloglucosidase/glucose oxidase method (see Materials and Methods). (F) Western blot for glycogen synthase (GS) and phosphorylated GS
(pGS) in overnight fasted liver samples of four different animals per genotype. Weight markers: GS/pGS, 100 (top) and 75 kDa (bottom); actin,
37 kDa. Arrows indicate Par-1a/. (G) Ultrastructural characterization of liver tissue from WT (images a to c) and Par-1a/ littermates (images d
to f) after nutrient starvation for 24 h. (a) Toluidine blue-stained plastic section of starved WT liver at low magnification showing
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defective gluconeogenesis, we probed for UCP2 in fasted and
nonfasted liver samples but found similar protein levels (not
shown). Most recently, autophagy has been linked to lipid (91)
as well as glycogen/glucose homeostasis (55, 56). Therefore, we
monitored LC-3 as a marker for membrane formation and
early stages of autophagy but observed no differences (not
shown). The electron microscopic examination of livers from
fasted WT mice demonstrated irregularly shaped glycogen is-
lands (Fig. 5G, images a and b) and variably sized lipid vacu-
oles (5G, image b) in close proximity to mitochondria with
normal morphology (Fig. 5G, image c). In striking contrast,
livers from fasted Par-1a null mice did not have lipid vacuoles,
were completely depleted of glycogen (Fig. 5G, images d and
e), and had abundant autophagocytic vacuoles throughout the
hepatocytes (Fig. 5G, images e and f). These autophagic vacu-
oles were normally configured and frequently associated with
mitochondria (Fig. 5G, image f). Our ultrastructural findings
with WT mice indicate a catabolic state, whereas the findings in
Par-1a null liver are indicative of more extreme energy depri-
vation with the self digestion of organelles (Fig. 5G, image f).
Par-1b/Par-1a double mutants are not viable, and at least
one allele is necessary for embryonic survival. Cross-breeding
experiments were performed to obtain mice disrupted for both
Par-1a and Par-1b. After an initial experiment where 24 inter-
crosses were performed and only six of the nine possible ge-
notypes were obtained, genotype frequencies in ongoing HH
HH crosses were monitored. Eventually two of the three miss-
ing genotypes were obtained (Fig. 6A) but at a substantial
deviation from expected Mendelian ratio (probability of
2.176911e198 using the chi-square test with 8 degrees of free-
dom) and with a complete absence of mice lacking both Par-1a
and Par-1b (KK). In addition, there was a drastic reduction in
the numbers of KH and HK mice (0.5 and 2.7%, respectively).
Instead of the expected 12.5% (corresponding to an estimated
308 mice; gray background in Fig. 6A), we obtained a total of
14 KH and 69 HK mice (out of 2,466). Pregnant females that
had been superovulated from HH intercrosses were sacrificed,
and fetuses at 10.5 (n  4) or 8.5 (n  4) dpc were isolated.
None of the obtained sets of embryos (total n  31) included
the KK genotype (expected frequency, 
2 mice). All other
genotypes were obtained (not shown). These results illustrate
that Par-1b/Par-1a double mutants are not viable and that at
least one allele of either Par-1a or Par-1b is necessary for
viability and likely embryonic survival.
When normalized to age-matched WT controls, Par-1b null
mice are 
20% reduced in body weight (43) and Par-1a null
mice are 
9% reduced in body weight (this study). The loss of
one Par-1a allele in Par-1b null mice (KH) led to a more-
pronounced reduction in body weight (30%) than that ob-
served in Par-1a null mice containing a single allele of Par-1b
(HK, 23%) (Fig. 6B). HK and KH mice were not healthy, and
a high proportion of these animals died shortly after birth (not
shown). The severity of phenotypes observed in each genotype
followed the order KK  KH  HK  KW  WK  WW and
suggests an intriguing gene dosage effect at the organism level.
DISCUSSION
This study describes metabolic phenotypes arising in mice
disrupted for Par-1a and the consequences of intercrossing of
Par-1a- with Par-1b-deficient mice. Par-1a null mice are hyper-
metabolic and show reduced body weight, decreased adiposity,
resistance to hepatic steatosis, and hypofertility; these features
are reminiscent of the Par-1b null phenotype (43). Metabolic
phenotypes of Par-1a null mice not shared by Par-1b null mice
include (i) hepatic glycogen depletion after starvation associ-
ated with hypoketotic hypoglycemia and increased autophagic
vacuoles in the liver, and (ii) a modestly reduced glucose up-
take by WAT when mice were fed a standard chow diet. Fea-
tures observed in Par-1b null mice but not in Par-1a mice
include (i) hyperphagy (the food intake of Par-1a null mice was
equivalent to that of controls); (ii) reduced serum insulin levels
the accumulation of lipid droplets (open arrow) and glycogen (solid arrow). (b) Electron microscopic examination of WT hepatocytes at low-power
magnification showing a large number of variable-sized lipid vacuoles (open arrow) and glycogen islands (solid arrow). (c) Detail of cytoplasmic
organization with lipid droplets (open arrow) surrounded by numerous mitochondria (asterisks). (d) Toluidine blue-stained plastic section of
starved Par-1a/ liver at low magnification shows the absence of lipid droplets and glycogen. (e) Electron microscopic examination of Par-1a/
hepatocytes at low-power magnification showing the absence of glycogen and lipid vacuoles. (f) Detailed EM view of cytoplasmic organization with
numerous autophagosomes (arrows) consisting of isolated membranes surrounding cytosolic material (top, so-called myelin figures; bottom,
ingested rough endoplasmic reticulum). Note the close proximity of autophagocytic vacuoles and mitochondria (asterisk).
FIG. 6. Par-1b//Par-1a/ double knockout mice are not viable,
and breeding experiments support ranked redundancy between iso-
forms. (A) Survival analysis of the offspring from matings of double-
heterozygous Par-1a/b mutant mice. The black bars plot the observed
frequency of the indicated genotypes as a percentage of the total,
whereas the gray background indicates the expected frequency based
on Mendelian inheritance (n  2,466). (B) Comparison of body
weights for five of the obtained genotypes from panel A. Weight is
normalized to that of WT littermates (HK, n  6 mice at 15 to 20
weeks versus control WT [n  6]; KH [embryonic day 17 postcoitus],
n  12 versus age-matched control WT [n  8; from the same litter]).
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under both fed and fasting conditions on a standard CD (se-
rum insulin levels in Par-1a null mice were lower than those
measured in WT littermates fed an HFD but not standard
CD); (iii) increased insulin sensitivity on standard CD (Par-1a
null mice were insulin sensitive on an HFD but not standard
CD); (iv) resistance to HFD-induced weight gain (Par-1a null
mice showed a reduced rate of weight gain relative to that of
control littermates when fed an HFD); (v) enhanced glucose
uptake in BAT (the loss of Par-1a did not affect glucose uptake
in BAT under any condition); and (vi) resistance to hepatic
steatosis accompanied by enhanced glucose uptake in liver
(Par-1a null mice; resistance to hepatic steatosis was not ac-
companied by enhanced hepatic glucose uptake).
Strikingly, Par-1a null mice on HFD exhibited profound
resistance to the development of glucose intolerance (Fig. 3D)
as well as delayed weight gain on HFD (Fig. 2A). These find-
ings most likely are related to peripheral insulin hypersensitiv-
ity, as illustrated by resistance to glucose intolerance and de-
creased insulin secretion during GTT (on HFD). Par-1a null
livers maintained resistance to steatosis despite HFD challenge
(Fig. 5A and B). However, the adiposity and WAT glucose
uptake measured in Par-1a null mice fed an HFD were similar
to those of WT littermates fed the same diet. Although this
study does not provide conclusive evidence for a hepatocyte-
autonomous role for either Par-1a or Par-1b in lipogenesis, the
striking resistance to hepatic steatosis seen in both models
suggests such a function. Upon short-term starvation, the livers
of Par-1a null mice exhibited profound defects in both glyco-
gen storage and glucose mobilization (gluconeogenesis), phe-
notypes not observed in Par-1b null mice. The depletion of
both lipid and glycogen stores, the upregulation of glycogen
synthase, and the activation of autophagy are observed in the
livers of Par-1a null mice. The increase in total glycogen syn-
thase might be a compensatory response in light of the de-
creased glycogen storage. However, we also observe an in-
crease in the inhibited (phosphorylated) form of glycogen
synthase. Thus, it is unclear whether the net glycogen synthase
activity is altered in the livers of Par-1a/ mice. Our ultra-
structural findings of increased autophagy in the absence of
glycogen or lipid vacuoles in the livers of Par-1a null mice
suggests substantial energy deprivation with the self digestion
of organelles. The absence of both hepatic glycogen mobiliza-
tion and gluconeogenesis required to maintain normal blood
glucose levels during starvation in turn leads to hypoglycemia
and hypoketosis in Par-1a null mice.
The underlying molecular mechanisms driving the hypermeta-
bolic phenotype, resistance to hepatic steatosis in Par-1a null
mice, and the inability of these mice to maintain metabolic ho-
meostasis during periods of starvation remain unclear. The reg-
ulation of lipogenesis, glucose metabolism, and autophagy are
coordinated, at least in part, through the Par-1-related kinase
AMPK. It is tempting to speculate that Par-1 regulates these
pathways via a common mechanism. To test this, we monitored
the activation state of the mTOR pathway by assessing levels of
phospho- and total AKT, phospho- and total AMPK, phospho-
and total p70S6K, phospho- and total pS6 ribosomal protein, and
LC-3 in the livers of Par-1-deficient mice during starvation and
upon refeeding. We did not observe any consistent alterations in
the levels or activation state of these proteins. Curiously, although
both AMPK and SIK kinases negatively regulate lipogenesis via
SREBP1c, the phenotypes of Par-1 null mice suggest that Par-1 is
a positive regulator for lipogenesis in adipocytes and hepatocytes.
The molecular mechanism underlying the phenotypes of Par-1a
null mice will require tissue-specific deletion and the identifica-
tion of specific downstream targets of Par-1a mediating these
effects.
Another major finding of this study is that Par-1b compen-
sates more effectively for the loss of Par-1a than the reverse,
and that embryonic survival requires the presence of at least
one allele of Par-1a/b. Moreover, the presence of only one
Par-1a allele in the complete absence of Par-1b conveys the
most severe phenotype (growth restriction), supporting the
notion of ranked redundancy with the most severe phenotype
observed in the very rare KH (Par-1b//Par-1a/) mutant.
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